Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaye J Williams

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Molecular Cancer Therapeutics|December 10, 2009
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenograftsKaye J Williams, Mark R Albertella, Brian Fitzpatrick, et al.
Cancer Research|February 7, 2002
Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathwayJohn R Griffiths, Paul M J McSheehy, Simon P Robinson, et al.
Scientific Reports|November 16, 2018
Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transportersManal Mehibel, Fernando Ortiz-Martinez, Nadine Voelxen, et al.
Pharmaceutics|October 26, 2024
Targeting Hypoxia-Inducible Factor-1α in Pancreatic Cancer: siRNA Delivery Using Hyaluronic Acid-Displaying NanoparticlesAlice Spadea, Annalisa Tirella, Julio Manuel Rios de la Rosa, et al.
BMC Urology|July 2, 2021
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancerBecky A S Bibby, Niluja Thiruthaneeswaran, Lingjian Yang, et al.
Cancer Research|May 23, 2002
Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factorGisele Höpfl, Roland H Wenger, Urs Ziegler, et al.
Communications Medicine|April 1, 2026
Longitudinal plasma nano-proteomics reveals acute systemic responses to radiotherapy and predictive biomarkers of late toxicityHanan Abumanhal-Masarweh, Salam A Assi, Xinming Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 10, 2005
Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1Kaye J Williams, Brian A Telfer, Dia Xenaki, et al.
Neuro-Oncology|April 1, 2020
Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastomaJessica T Taylor, Stuart Ellison, Alina Pandele, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 2024
Dose-dependent changes in cardiac function, strain and remodelling in a preclinical model of heart base irradiationMihaela Ghita-Pettigrew, Kevin S Edgar, Refik Kuburas, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Molecular Cancer Therapeutics|December 10, 2009
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenograftsKaye J Williams, Mark R Albertella, Brian Fitzpatrick, et al.
Cancer Research|February 7, 2002
Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathwayJohn R Griffiths, Paul M J McSheehy, Simon P Robinson, et al.
Scientific Reports|November 16, 2018
Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transportersManal Mehibel, Fernando Ortiz-Martinez, Nadine Voelxen, et al.
Pharmaceutics|October 26, 2024
Targeting Hypoxia-Inducible Factor-1α in Pancreatic Cancer: siRNA Delivery Using Hyaluronic Acid-Displaying NanoparticlesAlice Spadea, Annalisa Tirella, Julio Manuel Rios de la Rosa, et al.
BMC Urology|July 2, 2021
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancerBecky A S Bibby, Niluja Thiruthaneeswaran, Lingjian Yang, et al.
Cancer Research|May 23, 2002
Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factorGisele Höpfl, Roland H Wenger, Urs Ziegler, et al.
Communications Medicine|April 1, 2026
Longitudinal plasma nano-proteomics reveals acute systemic responses to radiotherapy and predictive biomarkers of late toxicityHanan Abumanhal-Masarweh, Salam A Assi, Xinming Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 10, 2005
Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1Kaye J Williams, Brian A Telfer, Dia Xenaki, et al.
Neuro-Oncology|April 1, 2020
Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastomaJessica T Taylor, Stuart Ellison, Alina Pandele, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 2024
Dose-dependent changes in cardiac function, strain and remodelling in a preclinical model of heart base irradiationMihaela Ghita-Pettigrew, Kevin S Edgar, Refik Kuburas, et al.
Pageof 10